کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2145982 | 1088842 | 2009 | 14 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
تحقیقات سرطان
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530 Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530](/preview/png/2145982.png)
چکیده انگلیسی
AZD0530, an orally available Src inhibitor, demonstrated potent antimigratory and anti-invasive effects in vitro, and inhibited metastasis in a murine model of bladder cancer. Antiproliferative activity of AZD0530 in vitro varied between cell lines (IC50 0.2 -> 10 μM). AZD0530 inhibited tumor growth in 4/10 xenograft models tested and dynamically inhibited in vivo phosphorylation of Src substrates paxillin and FAK in both growth-inhibition-resistant and -sensitive xenografts. The activity of AZD0530 in NBT-II bladder cancer cells in vitro was consistent with inhibition of cell migration and stabilization of cell-cell adhesion. These data suggest a dominant anti-invasive pharmacology for AZD0530 that may limit tumor progression in a range of cancers. AZD0530 is currently in Phase II clinical trials.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Molecular Oncology - Volume 3, Issue 3, June 2009, Pages 248-261
Journal: Molecular Oncology - Volume 3, Issue 3, June 2009, Pages 248-261
نویسندگان
Tim P. Green, Mike Fennell, Robin Whittaker, Jon Curwen, Vivien Jacobs, Jack Allen, Armelle Logie, Judith Hargreaves, D. Mark Hickinson, Robert W. Wilkinson, Paul Elvin, Brigitte Boyer, Neil Carragher, Patrick A. Plé, Alun Bermingham,